AMYT:NSD-Amryt Pharma plc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 10.67

Change

+0.36 (+3.49)%

Market Cap

USD 0.39B

Volume

0.07M

Avg Analyst Target

USD 27.00 (+153.05%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Amryt Pharma plc, a commercial-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy. It also develops FILSUVEZ drug candidate, which is in Phase 3 EASE trial for the treatment of severe epidermolysis bullosa (EB), a rare and genetic skin disease; and AP103 that is in preclinical stage for the treatment of patients with recessive dystrophic EB, a subset of EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-08-02 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
CGC Canopy Growth Corporation

-0.11 (-0.58%)

USD7.46B N/A N/A
APHA Tilray, Inc

N/A

USD6.86B 60.60 454.68
TLRY Tilray, Inc

N/A

USD6.56B N/A N/A
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
CRON Cronos Group Inc

-0.04 (-0.54%)

USD2.75B 37.00 N/A
PCRX Pacira BioSciences, Inc

+0.27 (+0.46%)

USD2.60B 17.73 37.25
IRWD Ironwood Pharmaceuticals, Inc

N/A

USD2.15B 14.93 12.02
ORGO Organogenesis Holdings Inc

-0.64 (-4.17%)

USD1.97B 41.46 30.47
SNDL Sundial Growers Inc

-0.01 (-1.26%)

USD1.53B -99,999.99 N/A

ETFs Containing AMYT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -24.65% 28% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.65% 28% F 15% F
Trailing 12 Months  
Capital Gain -5.16% 46% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.16% 46% F 20% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -0.01% 58% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.01% 58% F 21% F
Risk Return Profile  
Volatility (Standard Deviation) 0.88% 100% A+ 100% A+
Risk Adjusted Return -0.97% 58% F 20% F
Market Capitalization 0.39B 56% F 48% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 7.02 25% F 21% F
Price / Cash Flow Ratio 14.53 11% F 29% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -118.53% 25% F 17% F
Return on Invested Capital -15.69% 54% F 30% F
Return on Assets -0.61% 75% C 43% F
Debt to Equity Ratio 284.82% 12% F 6% F
Technical Ratios  
Short Ratio 15.96 10% F 2% F
Short Percent 12.74% 25% F 14% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector